Trial Profile

A single-arm, open-label, phase I clinical study on the safety and efficacy of ARX788 in the treatment of patients with HER2-positive advanced metastatic gastric cancer and gastroesophageal junction adenocarcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Oct 2021 According to an Ambrx media release, trial has completed the enrollment of 30 patients.
04 Oct 2021 Positive interim data from this trial were presented at The Chinese Society of Clinical Oncology (CSCO).
04 Oct 2021 Positive interim data (data as of June 30, 2021) published in an Ambrx Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com